Seventh International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma

项目摘要 我们建议组织和举办第七届儿童、青少年和 年轻成人（CAYA）非霍奇金淋巴瘤（NHL）在纽约州纽约市洲际酒店， 2022年10月20日至23日。第一、第二和第四次专题讨论会在纽约喜来登酒店举行， 2003年、2006年和2012年分别在纽约州纽约市、法兰克福、德国、2009年第三座、瓦雷塞、意大利第五座 2015年和2018年在荷兰鹿特丹举行的第六届。目前仍然影响CAYA患者的问题 包括来自低社会经济资源国家的CAYA患者预后不良， 在复发/进展的患者中，不可接受的短期和长期发病率以及缺乏关于 与CAYA NHL相关的基因组、表观遗传和免疫学畸变。不幸的是， 有限的教育资源可用于增加我们对基础生物学的理解， 耐药机制，新的翻译和靶向治疗的发展和长期的 治疗这种罕见疾病的长期效果和几乎可以忽略的教育会议支持 来自NIH和制药/生物技术公司支持国际会议。的 主要目的：1）鉴定成熟的乳腺癌病理学中新的基因组、表观遗传和免疫组学畸变， CAYA中的B-NHL、ALCL、成熟NK/T、淋巴母细胞淋巴瘤和罕见NHL; 2）确定安全性和 新的靶向细胞和体液免疫疗法在CAYA NHL患者中的疗效; 3）回顾 AYA与NHL和HL的“科学状态”; 4）提高对健康和生存的理解 5）促进CAYA与NHL的研究和治疗方案的合作， 低社会经济资源国家。次要目标：1）为研究者创造机会， 培训和年轻的教师主持会议，介绍他们的研究和接口与更高级的 （2）加强与国际多学科小组的沟通和合作， CAYA NHL基础、转化和临床研究的研究者; 3）提供机会， CAYA NHL为资源较少的社会经济调查人员提供的最先进的教育计划 环境;和4）促进和弥合儿童与AYA NHL之间的临床和科学差距， 促进儿科和内科肿瘤学家之间的合作。第七届国际 研讨会将最有可能增加我们的基本，翻译和临床状态的理解， 这组罕见病的科学研究，提供了一个机会和平台， 让年轻和资深的多学科和多国调查人员参与， 合作研究，最终将导致开发毒性更小，更具体的 分子、免疫和小分子靶向治疗，用于未来几代患有 CAYA NHL。

PROJECT SUMMARY We propose to organize and conduct the Seventh International Symposium on Childhood, Adolescent and Young Adult (CAYA) Non-Hodgkin Lymphoma (NHL) at the Intercontinental Hotel in New York City, NY, on October 20-23, 2022. The first, second and fourth symposia were held at the New York Sheraton Hotel and Towers in NYC, NY, in 2003, 2006 and 2012, the third in Frankfurt, Germany in 2009, the fifth in Varese, Italy in 2015 and the sixth in 2018, in Rotterdam, The Netherlands. Current problems that still affect CAYA patients with NHL include poor prognosis of CAYA patients from low socioeconomic resourced countries, poor outcome in patients who relapse/progress, unacceptable short and long-term morbidity and a paucity of information on genomic, epigenetic and immunological aberrations associated with CAYA NHL. Unfortunately, there have been limited educational resources available to increasing our understanding of the basic biology, mechanisms of drug resistance, development of novel translational and targeted therapies and long term effects of treatment of this orphan disease and almost negligible educational conference support from the NIH and pharmaceutical/biotechnology companies supporting international conferences. The primary objectives:1) Identify new genomic, epigenetic and immunomic aberrations in the pathology of mature B-NHL, ALCL, mature NK/T, lymphoblastic lymphoma, and rare NHL in CAYA; 2) To determine the safety and efficacy of novel targeted cellular and humoral immunotherapy in CAYA patients with NHL; 3) To review the ‘state of the science” in AYA with NHL and HL; 4) To enhance the understanding of wellness and survivorship of CAYA with NHL; and 5) To promote collaboration of research and treatment protocols in CAYA with NHL in low socioeconomic resourced countries. Secondary objectives: 1) To create an opportunity for investigators in training and young faculty to chair sessions, present their research and interface with more senior investigators; 2) to enhance communication and collaboration with a multidisciplinary group of international investigators in basic, translational and clinical research in CAYA NHL; 3) to provide an opportunity to conduct a state of the art educational program in CAYA NHL for investigators from less resourced socioeconomic environments; and 4) to facilitate and bridge the clinical and scientific gap between childhood vs AYA NHL and promote collaboration between pediatric and medical oncologists. The results of the Seventh International Symposium will most likely increase our understanding of the basic, translational and clinical state of the scientific research in this group of rare diseases and provide an opportunity and platform to engage young and senior multidisciplinary and multinational investigators to develop international collaborative research that will ultimately lead to the development of less toxic and more specific molecular, immune and small molecule targeted based therapies for future generations of patients with CAYA NHL.